What is the real function of the Liver 'Function' tests?

Ulster Medical Journal

Volumn 81, Issue 1, 2012, Pages 30-36

  Hall, Philip ^a   Cash, Johnny ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTATIC HEPATITIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ANALYSIS; ENZYME KINETICS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HYPERTRANSAMINASEMIA; LIVER FUNCTION TEST; NONALCOHOLIC FATTY LIVER; OBESITY; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING;

CHOLESTASIS; FATTY LIVER; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS;

EID: 84860894591     PISSN: 00416193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Anciaux ML, Pelletier G, Attali P, Meduri B, Liguory C, Etienne JP. Prospective study of clinical and biochemical features of symptomatic choledocholithiasis. Dig Dis Sci. 1986;31(5):449-53.
2. Nathwani RA, Kumar SR, Reynolds TB, Kaplowitz N. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol. 2005;100(2):295-8.
3. McClatchey K. Clinical Laboratory Medicine. Philadelphia: Lippincott Williams Wilkins; 2002.
4. Velayudham LS, Farrell GC. Drug-induced cholestasis. Expert Opin Drug Saf 2003;2(3):287-304.
5. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-67.
6. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31(4):1005-13.
7. Alempijevic T, Krstic M, Jesic R, Jovanovic I, Sokic MA, Kovacevic N et al. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World J Gastroenterol. 2009;15(5):591-4.
8. Treeprasertsuk S, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS et al. The predictors of the presence of varices in patients with primary sclerosing cholangitis. Hepatology 2010;51(4):1302-10.
9. Nyblom H, Nordlinder H, Olsson R. High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. Liver Int. 2007;27(5):694-9.
10. Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol. 1981;10(2):417-41.
11. Goldberg S, Mendenhall C, Anderson S, Garcia-Pont P, Kiernan T, Seeff L et al. VA Cooperative Study on Alcoholic Hepatitis. IV. The significance of clinically mild alcoholic hepatitis--describing the population with minimal hyperbilirubinemia. Am J Gastroenterol. 1986;81(11):1029-34.
12. Stranges S, Freudenheim JL, Muti P, Farinaro E, Russell M, Nochajski TH et al. Differential effects of alcohol drinking pattern on liver enzymes in men and women. Alcohol Clin Exp Res. 2004;28(6):949-56.
13. Cohen JA, Kaplan MM. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci. 1979;24(11):835-8.
14. Diehl AM, Potter J, Boitnott J, Van Duyn MA, Herlong HF, Mezey E. Relationship between pyridoxal 5'-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology 1984;86(4):632-6.
15. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94(4):1018-22.
16. Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004;39(4):336-9.
17. Kazemi-Shirazi L, Veloso MP, Frommlet F, Steindl-Munda P, Wrba F, Zehetmayer S et al. Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful? Wien Klin Wochenschr. 2008;120(1-2):25-30.
18. Marshall JB, Burnett DA, Zetterman RK, Sorrell MF. Clinical and biochemical course of alcoholic liver disease following sudden discontinuation of alcoholic consumption. Alcohol Clin Exp Res. 1983;7(3):312-5.
19. Narjes H, Nehmiz G. Effect of hospitalisation on liver enzymes in healthy subjects. Eur J Clin Pharmacol. 2000;56(4):329-33.
20. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57(10):1441-7.
21. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
22. Papadia FS, Marinari GM, Camerini G, Murelli F, Carlini F, Stabilini C et al. Liver damage in severely obese patients: a clinical-biochemicalmorphologic study on 1,000 liver biopsies. Obes Surg. 2004;14(7):952-8.
23. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846-54.
24. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95(3):734-9.
25. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30(6):1356-62.
26. Nazer H, Ede RJ, Mowat AP, Williams R. Wilson's disease: clinical presentation and use of prognostic index. Gut 1986;27(11):1377-81.
27. Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH, Jr. et al. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2008;48(4):1167-74.
28. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31 (Suppl 1):9-16.
29. Nguyen MH, Garcia RT, Trinh HN, Lam KD, Weiss G, Nguyen HA et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels. Am J Gastroenterol. 2009;104(9):2206-13.
30. Morgan M, Keeffe EB. Diagnosis and treatment of chronic hepatitis B: 2009 update. Minerva Gastroenterol. Dietol. 2009(1);55:5-22.
31. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001;96(11):3142-6.
32. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007;46(3):912-21.
33. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929-38.
34. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981;80(4):687-92.
35. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63(5):820-33.
36. Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2006;24(8):1197-205.
37. Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15(10):1254-61.
38. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367-79.
39. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007;46(2):582-9.
40. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31.
41. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43(5):1145-51.
42. Moussavian SN, Becker RC, Piepmeyer JL, Mezey E, Bozian RC. Serum gamma-glutamyl transpeptidase and chronic alcoholism. Influence of alcohol ingestion and liver disease. Dig Dis Sci. 1985;30(3):211-4.
43. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002;34(3):255-62.